Semaglutide vs Mazdutide
Semaglutide vs Mazdutide: GLP-1 only vs GLP-1 + glucagon dual agonist. China-approved Mazdutide vs the global standard.
The verdict
Semaglutide is the global GLP-1 standard, single-receptor, fully FDA-approved, years of real-world use. Mazdutide adds a glucagon arm on top of GLP-1, which brings a metabolic-rate boost, and it's already approved in China for obesity though not yet globally. If you want the worldwide-established option with the deepest track record, Semaglutide. Mazdutide is the more novel dual-mechanism pick, most relevant where it's actually approved and worth watching as the dual-agonist data matures.
Semaglutide is the first wave of modern weight-loss drugs, sold as Ozempic and Wegovy. Single-receptor version of Tirzepatide. Slightly less effective and slightly rougher side effects, but well-studied and widely available.
Mazdutide is a Chinese-developed GLP-1 + glucagon dual agonist, same class as Survodutide and Retatrutide. Approved in China in 2025 for obesity. The glucagon part adds a metabolic-rate bump on top of GLP-1's appetite suppression.
Which one should you pick?
Pick Semaglutide if beginners to glp-class peptides or users with insurance coverage on wegovy / ozempic.
Pick Mazdutide if users wanting a glp/glucagon agonist with cleaner side effect profile than survodutide reports or followers of chinese metabolic-drug development.
Still torn between Semaglutide and Mazdutide?
The AI Coach reads both, asks about your goal and experience, and tells you which one actually fits — plus how to dose and stack it. Free.